Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy.
The Cancer Risk Intake System (CRIS), a computerized program that "matches" objective cancer risks to appropriate risk management recommendations, was designed to facilitate patient-clinician discussion. We evaluated CRIS in primary care settings via a single-group, self-report, pretest-posttest design. Participants completed baseline telephone surveys, used CRIS during clinic visits, and completed follow-up surveys 1 to 2 months postvisit. Compared with proportions reporting having had discussions at baseline, significantly greater proportions of participants reported having discussed tamoxifen, genetic counseling, and colonoscopy, as appropriate, after using CRIS. Most (79%) reported CRIS had "caused" their discussion. CRIS is an easily used, disseminable program that showed promising results in primary care settings.
Skinner
Celette Sugg
CS
Duke University Medical Center, Durham, NC 27710, USA. celette.skinner@duke.edu
Rawl
Susan M
SM
Moser
Barry K
BK
Buchanan
Adam H
AH
Scott
Linda L
LL
Champion
Victoria L
VL
Schildkraut
Joellen M
JM
Parmigiani
Giovanni
G
Clark
Shelly
S
Lobach
David F
DF
Bastian
Lori A
LA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D003113:Colonoscopy; D003142:Communication; D003376:Counseling; D005260:Female; D005817:Genetic Counseling; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D010342:Patient Acceptance of Health Care; D010353:Patient Education as Topic / Q000379:methods; D010817:Physician-Patient Relations; D011320:Primary Health Care; D018570:Risk Assessment / Q000379:methods*; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen